

ABSENCE OF EXCESS BODY FATNESS

VOLUME 16

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Interventions, which met in Lyon, 5–12 April 2016

LYON, FRANCE - 2018

IARC HANDBOOKS OF
CANCER PREVENTION

2.2.2 Cancer of the oesophagus

There are two main histological subtypes of cancer of the oesophagus: adenocarcinoma and squamous cell carcinoma. Oesophageal squamous cell carcinoma arises from epithelial cells that line the oesophagus and typically occurs in the upper and middle parts of the oesophagus. Oesophageal adenocarcinoma originates from glandular cells; it occurs in the lower portion of the oesophagus and can spread into the gastric cardia.

In 2001, the Working Group of the *IARC Handbook on weight control and physical activity* ([IARC, 2002](#)) concluded that there was *sufficient evidence* for a cancer-preventive effect of avoidance of weight gain for oesophageal adenocarcinoma. Although recent pathological classification recognizes the histological similarity between oesophageal adenocarcinoma and gastric cardia cancer, most epidemiological studies classify gastric cardia cancer with stomach cancer, and therefore these studies are considered in Section 2.2.3. Also, because evidence to date strongly suggests differences in etiological factors between oesophageal adenocarcinoma and squamous cell carcinoma, the results are presented separately for each histological subtype, and no results are presented for oesophageal cancer overall.

(a) Cohort studies

See [Table 2.2.2a](#).

(i) Adenocarcinoma of the oesophagus

Several cohort studies (with at least 75 incident cases) have been published since the previous IARC evaluation ([IARC, 2002](#)). In all of those studies, BMI and/or weight were positively associated with risk ([Engeland et al., 2004](#); [Lindblad et al., 2005](#); [Samanic et al., 2006](#); [Merry et al., 2007](#); [Reeves et al., 2007](#); [Abnet et al., 2008](#); [Corley et al., 2008](#); [O'Doherty et al., 2012](#); [Lindkvist et al., 2014](#); [Steffen et al., 2015](#)).

Associations were similar across follow-up periods in one study ([Engeland et al., 2004](#)) and in another study that excluded the first 5 years of follow-up ([Abnet et al., 2008](#)). There did not appear to be any meaningful differences in associations when stratifying by smoking status ([O'Doherty et al., 2012](#); [Lindkvist et al., 2014](#)) or when limiting results to non-smokers or never-smokers only ([Reeves et al., 2007](#); [Abnet et al., 2008](#)).

In a meta-analysis including five prospective studies ([Renehan et al., 2008](#)), a relative risk of 1.5 for a 5 kg/m² increase in BMI at baseline was reported, with similar values in men and in women.

Few studies have examined the association between BMI measured at younger ages and subsequent risk of oesophageal adenocarcinoma. In the Netherlands Cohort Study, there was evidence of a positive association between high BMI at age 20 years and risk, although the relative risk estimate was not statistically significant ([Merry et al., 2007](#)).

The association between BMI change and incidence of oesophageal adenocarcinoma was examined in two prospective studies ([Samanic et al., 2006](#); [Merry et al., 2007](#)). The first study, which considered BMI change during a period of 6 years, did not find evidence for a positive association [the analysis was based on only 28 incident cases] ([Samanic et al., 2006](#)). The second study, which included 113 cases, found that a 1 kg/m² increase in BMI from age 20 years to baseline was significantly associated with a 14% higher risk (95% CI, 1.06–1.23) ([Merry et al., 2007](#)).

There have been few prospective studies of abdominal fatness in relation to risk of oesophageal adenocarcinoma. A study nested within the Multiphasic Health Check-up cohort of Kaiser Permanente Northern California members observed a positive association between sagittal abdominal diameter [distance from the anterior to the posterior of the abdomen] and incidence

of oesophageal adenocarcinoma ([Corley et al., 2008](#)). Similarly, strong positive associations were reported of both waist circumference and waist-to-hip ratio with incidence of oesophageal adenocarcinoma in the National Institutes of Health–AARP Diet and Health Study (NIH-AARP) cohort ($P_{\text{trend}} \leq 0.01$ for both) ([O’Doherty et al., 2012](#)) and with oesophageal adenocarcinoma incidence/mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC) study ($P_{\text{trend}} \leq 0.0001$) ([Steffen et al., 2015](#)).

(ii) *Squamous cell carcinoma of the oesophagus*

Since 2001, the association between BMI and/or weight assessed at baseline and the incidence and/or mortality of oesophageal squamous cell carcinoma has been examined in at least nine individual prospective studies ([Engeland et al., 2004](#); [Lindblad et al., 2005](#); [Tran et al., 2005](#); [Samanic et al., 2006](#); [Merry et al., 2007](#); [Reeves et al., 2007](#); [Corley et al., 2008](#); [Steffen et al., 2009](#); [Lindkvist et al., 2014](#)) and in one meta-analysis ([Renehan et al., 2008](#)). In all of the studies, BMI and/or weight were inversely associated with risk. Notably, higher risks were found in the lowest BMI categories (i.e. BMI < 20 kg/m²) compared with categories within the normal range of BMI, whereas lower risks were observed in the overweight and obese categories. Although most studies adjusted for tobacco use, not all studies included alcohol consumption, another strong risk factor for oesophageal squamous cell carcinoma in their model. Furthermore, in two studies that stratified by smoking status, there was an inverse association in current smokers but no association in non-smokers [supporting a possible confounding effect of tobacco smoking] ([Steffen et al., 2009](#); [Lindkvist et al., 2014](#)). In contrast, in the Million Women Study, an inverse association with both incidence and mortality of oesophageal squamous cell carcinoma was noted even in the never-smokers group ([Reeves et al.,](#)

[2007](#)). An inverse association was also observed in the only study in Asia, which included 1958 incident cases in China ([Tran et al., 2005](#)). There was no evidence of differences in associations based on follow-up time ([Engeland et al., 2004](#)).

A meta-analysis of five prospective studies by [Renehan et al. \(2008\)](#) reported a relative risk per 5 kg/m² increase in BMI of 0.71 (95% CI, 0.60–0.85) in men and 0.57 (95% CI, 0.47–0.69) in women.

The association between BMI measured at age 20 years and risk of oesophageal squamous cell carcinoma was examined in the Netherlands Cohort Study ([Merry et al., 2007](#)). The relative risk for BMI ≥ 25 kg/m² compared with BMI 20–21.4 kg/m² was 2.49 (95% CI, 1.15–5.40), but there was no evidence of dose–response [$P_{\text{trend}} = 0.58$]. In that study, weight loss from age 20 years to baseline was associated with a statistically significant increased risk, with a relative risk of 2.57, but there was no evidence that weight gain was associated with risk.

Only two prospective studies examined measures of abdominal fatness in relation to risk of oesophageal squamous cell carcinoma. In the Kaiser Permanente Multiphasic Health Check-up nested case–control study, there was no association between sagittal abdominal diameter and risk ([Corley et al., 2008](#)), whereas in the EPIC study, there was some evidence of a weak inverse trend of waist circumference with incidence/mortality ($P_{\text{trend}} = 0.08$) ([Steffen et al., 2009](#)).

(b) *Case–control studies*

See [Table 2.2.2b](#).

(i) *Adenocarcinoma of the oesophagus*

Of the case–control studies reporting on oesophageal adenocarcinoma, most studies showed increases of 2.5-fold and higher in risk of oesophageal adenocarcinoma when comparing the highest and lowest BMI categories, although in a few studies these associations were not statistically significant. When assessed, adjustments

for self-reported frequency or severity, or stratification by presence or absence of gastric reflux symptoms did not substantially alter the relative risk estimates ([Chow et al., 1998](#); [Lagergren et al., 1999](#); [de Jonge et al., 2006](#); [Anderson et al., 2007](#); [Löfdahl et al., 2008](#); [Whiteman et al., 2008](#); [Olsen et al., 2011](#)).

A pooled analysis of data from 10 case-control studies and 2 cohort studies ([Hoyo et al., 2012](#)), including a total of 3719 adenocarcinoma cases and 10 481 controls, showed significant trends of increasing adenocarcinoma risk with increasing BMI, up to odds ratios of 4.76 (95% CI, 2.96–7.66) for oesophageal adenocarcinoma and 3.07 (95% CI, 1.89–4.99) for oesophagogastric junction adenocarcinoma when comparing BMI ≥ 40 kg/m² with BMI < 25 kg/m². Subset analyses showed similar increases in risk of adenocarcinoma when stratifying by symptoms of gastro-oesophageal reflux disease. No differences in associations were observed by sex.

(ii) *Squamous cell carcinoma of the oesophagus*

For oesophageal squamous cell carcinoma, several case-control studies reported an inverse association between risk and recent BMI ([Vaughan et al., 1995](#); [Chow et al., 1998](#); [Lahmann et al., 2012](#)), and this inverse association was observed within both smokers and never-smokers ([Lahmann et al., 2012](#)). Of the two studies that investigated the association of risk of oesophageal squamous cell carcinoma with recalled BMI at age 20 years, one found a non-significant decrease in risk in relation to higher BMI ([Lahmann et al., 2012](#)), whereas the other study, based on a total of 167 cases in Sweden, showed an increase in risk with higher BMI ([Lagergren et al., 1999](#)).

(c) *Mendelian randomization studies*

See [Table 2.2.2c](#).

One Mendelian randomization study estimated the causal association between BMI and risk of oesophageal adenocarcinoma ([Thrift et al., 2014](#)). Using a genetic risk score based on 29 SNPs previously shown to be associated with BMI ([Speliotes et al., 2010](#)), this Mendelian randomization study showed that each 1 kg/m² increase in BMI was associated with a 23% increase in risk (95% CI, 6–43%; $P = 0.01$), compared with a 6% increase in risk (95% CI, 5–8%; $P < 0.001$) observed in the same sample by conventional epidemiological analyses.

Table 2.2.2a Cohort studies of measures of body fatness and cancer of the oesophagus

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
<i>Adenocarcinoma</i>							
Engeland et al. (2004)	Men: 963 709 Women: 1 038 010 Incidence	Oesophageal adenocarcinoma ICD-7: 150	BMI < 18.5 18.5–24.9 25–29.9 ≥ 30 [<i>P</i> _{trend}]	448 total	Men: – 1.00 1.80 (1.48–2.19) 2.58 (1.81–3.68) [< 0.001]	Age at measurement, height, birth cohort	
Norwegian cohort Norway 1963–2002			BMI < 18.5 18.5–24.9 25–29.9 ≥ 30 [<i>P</i> _{trend}]	127 total	Women: 4.07 (1.44–11) 1.00 1.64 (1.08–2.49) 2.06 (1.25–3.39) [0.002]		
Lindblad et al. (2005)	10 287 Men and women Incidence	Oesophageal adenocarcinoma	BMI < 20 20–24 25–29 ≥ 30 [<i>P</i> _{trend}]	8 49 94 36	1.44 (0.67–3.10) 1.00 1.68 (1.18–2.40) 1.93 (1.24–3.01) [0.005]	Age, sex, calendar year, smoking, alcohol consumption, reflux	
Case-control study nested in General Practitioner Research Database United Kingdom 1994–2001							
Samanic et al. (2006)	362 552 Men Incidence	Oesophageal adenocarcinoma	BMI 18.5–24.9 25–29.9 ≥ 30 [<i>P</i> _{trend}]	34 38 10	1.00 1.58 (0.98–2.53) 2.72 (1.33–5.55) [< 0.01]	Attained age (10-yr interval), calendar year, smoking	
Swedish Construction Worker Cohort Sweden 1958–1999							

Table 2.2.2a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Samanic et al. (2006) (cont.)			BMI, 6-yr change -4% to +4.9%	19	1.00		
			5-9.9%	3	0.44 (0.13-1.49)		
			10-14.9%	5	2.24 (0.81-6.21)		
			> 15% [<i>P</i> _{trend}]	1	1.21 (0.16-9.45) [> 0.5]		
Merry et al. (2007) Netherlands Cohort Study The Netherlands 1986-1999	4774 (case- cohort sample from 120 852 main cohort) Men and women Incidence	Oesophageal adenocarcinoma ICD-10: C15 Histology: 8140- 8141, 8190-8231, 8260-8263, 8310, 8430, 8480-8490, 8560, 8570-8572	BMI at baseline < 20 20-24.9 25-29.9 ≥ 30 [<i>P</i> _{trend}] per 1 kg/m ² BMI at age 20 yr < 20 20-21.4 21.5-22.9 23.0-24.9 ≥ 25 [<i>P</i> _{trend}] per 1 kg/m ² BMI change, age 20 yr to baseline < 0 0-3.9 4-7.9 ≥ 8 [<i>P</i> _{trend}] per 1 kg/m ²	3 51 60 19 21 24 37 18 13 8 51 37 17 22 27 30 48	1.29 (0.40-4.16) 1.00 1.40 (0.95-2.04) 3.96 (2.27-6.88) [0.001] 1.14 (1.08-1.21) 1.07 (0.59-1.94) 1.00 1.61 (0.95-2.72) 1.02 (0.55-1.90) 1.97 (0.99-3.94) [0.17] 1.04 (0.95-1.14) 0.75 (0.34-1.64) 1.00 1.34 (0.86-2.08) 3.41 (1.88-6.18) [0.001] 1.14 (1.06-1.23)	Age, sex For BMI change only: adjustment for BMI at age 20 yr	First year of follow-up excluded from the analyses
Reeves et al. (2007) Million Women Study United Kingdom 1996-2005	1 222 630 Women Incidence and mortality	Oesophageal adenocarcinoma ICD-10: C15	BMI < 22.5 22.5-24.9 25-27.4 27.5-29.9 ≥ 30 per 10 kg/m ²	Incidence: 22 27 30 23 48	1.06 (0.70-1.62) 1.00 (0.68-1.46) 1.28 (0.90-1.83) 1.57 (1.04-2.36) 2.54 (1.89-3.41) 2.38 (1.59-3.56)	Age, geographical region, SES, reproductive history, smoking status, alcohol consumption, physical activity	Results remained significant after excluding never- smokers and excluding the first 2 yr of follow-up

Table 2.2.2a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Reeves et al. (2007) (cont.)			BMI < 22.5 22.5–24.9 25–27.4 27.5–29.9 ≥ 30 per 10 kg/m ²	Mortality: 20 19 20 15 37	1.35 (0.87–2.11) 1.00 (0.64–1.57) 1.21 (0.78–1.87) 1.44 (0.87–2.39) 2.75 (1.97–3.85) 2.24 (1.40–3.58)		
Abnet et al. (2008) NIH-AARP cohort USA 1995–2003	480 475 Men and women Incidence	Oesophageal adenocarcinoma ICD-10: C15.0–15.9 Histology: “adenocarcinoma”	BMI < 18.5 18.5–24.9 25–29.9 30–34.9 ≥ 35	2 71 194 77 27	1.61 (0.39–6.55) 1.00 1.65 (1.26–2.18) 1.91 (1.38–2.66) 2.27 (1.44–3.59)	Age, sex, cigarette smoking, alcohol consumption, education level, physical activity	Results were stable after excluding the first 5 yr of follow-up
Corley et al. (2008) Nested case-control of Kaiser Permanente Multiphasic Health Check-up cohort USA 1964–1973	3150 Men and women Incidence	Oesophageal adenocarcinoma ICD-10: C15.0–15.9 Histology: 8140–8573	BMI < 18.5 18.5–24.9 25–29.9 ≥ 30 per 1 kg/m ² increase Sagittal abdominal diameter (cm) < 20 20–22.4 22.5–25 ≥ 25 per 1 cm increase	1 28 51 14 8 13 12 22 1.10 (1.03–1.17)	1.36 (0.12–15.52) 1.00 2.20 (1.31–3.67) 3.17 (1.43–7.04) 1.10 (1.04–1.17) 1.00 0.92 (0.31–2.74) 2.35 (0.78–7.12) 3.47 (1.29–9.33) 1.10 (1.03–1.17)	Age, sex, year of health check-up BMI results also adjusted for ethnicity	
Renehan et al. (2008) Meta-analysis 1966–2007	4 673 213 Men and women Incidence	Oesophageal adenocarcinoma	BMI per 5 kg/m ² increase BMI per 5 kg/m ² increase	Men: 1315 total Women: 735 total	1.52 (1.33–1.74) 1.51 (1.31–1.74)	Geographical region, age (all studies), and other factors (not in all studies) such as Western diet, alcohol consumption, medical conditions (e.g. type 2 diabetes, acromegaly), or physical activity	

Table 2.2.2a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
O'Doherty et al. (2012) NIH-AARP cohort USA 1995–2006	218 854 Men and women Incidence	Oesophageal adenocarcinoma ICD-10: C15.0–15.9 Histology: “adenocarcinoma”	BMI < 18.5 18.5–24.9 25–29.9 30–34.9 ≥ 35 [<i>P</i> _{trend}] Weight, quartiles (sex-specific) Q1 Q2 Q3 Q4 [<i>P</i> _{trend}] WC, quartiles (sex-specific) Q1 Q2 Q3 Q4 [<i>P</i> _{trend}]	0 59 119 64 11 41 58 53 101 37 49 79 88	– 1.00 1.30 (0.94–1.78) 2.28 (1.57–3.30) 2.11 (1.09–4.09) [< 0.01] 1.00 1.49 (0.99–2.23) 1.37 (0.89–2.10) 2.66 (1.76–4.02) [< 0.01] 1.00 1.36 (0.89–2.09) 1.51 (1.02–2.25) 2.01 (1.35–3.00) [< 0.01]	Age, sex, total energy intake, antacid use, aspirin use, NSAID use, marital status, diabetes, cigarette smoking, education level, ethnicity, alcohol consumption, physical activity, intake of red and white meat, intake of fruits and vegetables; for weight, also adjusted for height	Waist-to-hip ratio also significantly associated with risk (Q3 and Q4)
Lindkvist et al. (2014) Me-Can cohort (prospective cohorts) Austria, Norway, and Sweden 1972–2006	587 700 Men and women Incidence	Oesophageal adenocarcinoma ICD-7: 150	BMI, quintiles Q1 Q2 Q3 Q4 Q5 [<i>P</i> _{trend}] per 5 kg/m ²	5 18 18 31 42	1.00 3.37 (1.25–9.10) 3.17 (1.17–8.57) 5.19 (2.00–13.42) 7.34 (2.88–18.68) [< 0.0001] 1.78 (1.45–2.17)	Sex, age, study cohort, smoking status	

Table 2.2.2a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Steffen et al. (2015) EPIC cohort 10 European countries 1992–2008	391 456 Men and women Incidence/ mortality	Oesophageal adenocarcinoma ICD-10: C15	BMI, quintiles			Age at recruitment, centre, sex, education level, smoking, alcohol consumption, physical activity, diet, height	Sex-specific quintiles for weight, BMI, and WC. Cut-off points not provided, only the median values for each Positive associations with waist-to-hip ratio (Q4 and Q5)
			Q1	15	1.00		
			Q2	22	1.30 (0.67–2.52)		
			Q3	24	1.36 (0.71–2.62)		
			Q4	30	1.76 (0.93–3.31)		
			Q5	33	2.15 (1.14–4.05)		
			[<i>P</i> _{trend}]		[0.004]		
			Weight, quintiles				
			Q1	17	1.00		
			Q2	25	1.54 (0.82–2.88)		
			Q3	23	1.41 (0.74–2.70)		
			Q4	26	1.57 (0.82–3.01)		
			Q5	33	2.19 (1.14–4.21)		
			[<i>P</i> _{trend}]		[0.03]		
			WC, quintiles				
Q1	7	1.00					
Q2	22	2.78 (1.18–6.54)					
Q3	20	2.47 (1.03–5.92)					
Q4	26	3.19 (1.36–7.49)					
Q5	39	5.08 (2.21–11.7)					
[<i>P</i> _{trend}]		[< 0.0001]					
<i>Squamous cell carcinoma</i>							
Engeland et al. (2004) Population- based Norwegian cohort Norway 1963–2002	Men: 963 709 Incidence	Oesophageal squamous cell carcinoma ICD-7: 150	BMI	1023 total		Age at measurement, height, birth cohort	
			< 18.5		2.80 (1.73–4.54)		
			18.5–24.9		1.00		
			25–29.9		0.72 (0.63–0.82)		
			≥ 30		0.68 (0.50–0.93)		
	[<i>P</i> _{trend}]		[< 0.001]				
	Women: 1 038 010 Incidence	Oesophageal squamous cell carcinoma ICD-7: 150	BMI	472 total		Age at measurement, height, birth cohort	
			< 18.5		2.11 (1.23–3.62)		
			18.5–24.9		1.00		
			25–29.9		0.52 (0.42–0.65)		
≥ 30				0.43 (0.32–0.59)			
[<i>P</i> _{trend}]		[< 0.001]					

Table 2.2.2a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Lindblad et al. (2005) Case-control study nested in General Practitioner Research Database United Kingdom 1994–2001	10 140 Men and women Incidence	Oesophageal squamous cell carcinoma	BMI < 20 20–24 25–29 ≥ 30 [<i>P</i> _{trend}]	9 34 39 4	1.93 (0.90–4.11) 1.00 1.13 (0.71–1.80) 0.28 (0.10–0.79) [0.01]	Age, sex, calendar year, smoking, alcohol consumption, reflux	
Tran et al. (2005) Linxian General Population Trial China 1986–2001	29 584 Men and women Incidence	Oesophageal squamous cell carcinoma	BMI < 20 20–21 22 ≥ 23 [<i>P</i> _{trend}]	1958 total	1.00 0.96 (0.85–1.08) 0.80 (0.71–0.91) 0.81 (0.72–0.92) [< 0.001]	Age, sex	
Samanic et al. (2006) Swedish Construction Worker Cohort Sweden 1958–1999	362 552 Men Incidence	Oesophageal squamous cell carcinoma	BMI 18.5–24.9 25–29.9 ≥ 30 [<i>P</i> _{trend}]	134 57 13	1.00 0.53 (0.39–0.72) 0.77 (0.43–1.36) [< 0.01]	Attained age, calendar year, smoking	

Table 2.2.2a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Merry et al. (2007)	4774 (case-cohort sample from 120 852 main cohort) Men and women Incidence	Oesophageal squamous cell carcinoma ICD-10: C15 Histology: 8050–8076	BMI at baseline < 20 20–24.9 25–29.9 ≥ 30 [P _{trend}] per 1 kg/m ² BMI at age 20 yr < 20 20–21.4 21.5–22.9 23.0–24.9 ≥ 25 [P _{trend}] per 1 kg/m ² BMI change, age 20 yr to baseline < 0 0–3.9 4–7.9 ≥ 8 [P _{trend}] per 1 kg/m ²	9 51 26 6 22 16 11 13 12 18 32 16 8 106 63 52 21 21	2.21 (0.99–4.92) 1.00 0.63 (0.39–1.02) 0.93 (0.38–2.26) [0.04] 0.90 (0.82–0.98) 1.35 (0.70–2.62) 1.00 0.72 (0.33–1.57) 1.03 (0.48–2.21) 2.49 (1.15–5.40) [0.58] 1.07 (0.96–1.20) 2.57 (1.40–4.72) 1.00 0.73 (0.39–1.36) 1.39 (0.62–3.15) [0.10] 0.90 (0.81–1.00)	Age, sex, current smoking, cigarettes per day, number of years of smoking For BMI change only: adjustment for BMI at age 20 yr	
Reeves et al. (2007)	1 222 630 Women Incidence and mortality	Oesophageal squamous cell carcinoma ICD-10: C15	BMI < 22.5 22.5–24.9 25–27.4 27.5–29.9 ≥ 30 per 10 kg/m ²	Incidence: 106 63 52 21 21	2.04 (1.67–2.48) 1.00 (0.78–1.28) 0.96 (0.73–1.26) 0.61 (0.40–0.94) 0.47 (0.31–0.73) 0.26 (0.18–0.38)	Age, geographical region, SES, reproductive history, smoking status, alcohol consumption, physical activity	Negative associations remained stable in non-smokers and excluding the first 2 yr of follow-up

Table 2.2.2a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Reeves et al. (2007) (cont.)			BMI < 22.5 22.5–24.9 25–27.4 27.5–29.9 ≥ 30 per 10 kg/m ²	Mortality: 75 44 39 11 13	2.10 (1.66–2.65) 1.00 (0.74–1.35) 1.02 (0.75–1.40) 0.45 (0.25–0.82) 0.42 (0.24–0.73) 0.22 (0.14–0.35)		
Corley et al. (2008) Nested case-control of Kaiser Permanente Multiphasic Health Check- up cohort USA 1964–1973	3150 Men and women Incidence	Oesophageal squamous cell carcinoma ICD-10: C15.0–15.9 Histology 8050–8082	BMI < 18.5 18.5–24.9 25–29.9 ≥ 30 per 1 kg/m ² increase Sagittal abdominal diameter (cm) < 20 20–22.4 22.5–25 ≥ 25 per 1 cm increase	3 78 46 9 19 24 14 15	0.91 (0.19–4.29) 1.00 0.66 (0.44–1.00) 0.30 (0.13–0.72) 0.89 (0.84–0.94) 1.00 0.91 (0.43–1.94) 0.89 (0.35–2.24) 0.78 (0.32–1.92) 1.00 (0.94–1.06)	Matched for age, sex, year of health check-up BMI results also adjusted for ethnicity	
Renehan et al. (2008) Meta-analysis 1966–2007	4 673 213 Men and women Incidence	Oesophageal squamous cell carcinoma	BMI per 5 kg/m ² increase BMI per 5 kg/m ² increase	Men: 6201 total Women: 1114 total	0.71 (0.60–0.85) 0.57 (0.47–0.69)	Geographical region, age (all studies), and other factors (not in all studies) such as Western diet, alcohol consumption, medical conditions (e.g. type 2 diabetes, acromegaly), or physical activity	

Table 2.2.2a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Steffen et al. (2009) EPIC cohort 10 European countries 1992–2007	346 554 Men and women Incidence/mortality	Oesophageal squamous cell carcinoma ICD-10: C15	BMI, quintiles (sex-specific) Men: < 23.4 23.4–25.2 25.2–26.9 26.9–29.1 ≥ 29.2 [P _{trend}] Weight, quintiles Q1 Q2 Q3 Q4 Q5 [P _{trend}] WC, quintiles Q1 Q2 Q3 Q4 Q5 [P _{trend}]	Women: < 21.7 21.7–23.6 23.6–25.6 25.6–28.7 ≥ 28.8	42 1.00 22 0.47 (0.27–0.79) 15 0.31 (0.17–0.57) 14 0.27 (0.14–0.51) 17 0.26 (0.14–0.51) [< 0.0001] 41 1.00 28 0.61 (0.37–1.01) 14 0.30 (0.16–0.57) 10 0.19 (0.09–0.40) 17 0.33 (0.18–0.60) [< 0.0001] 23 1.00 19 0.76 (0.41–1.43) 23 0.78 (0.43–1.43) 16 0.51 (0.26–1.00) 22 0.62 (0.32–1.20) [0.08]	Age, study centre, education level, smoking, alcohol consumption, physical activity, consumption of fruits/vegetables/meat	BMI and WC were significantly inversely related to oesophageal squamous cell carcinoma only in smokers
Lindkvist et al. (2014) Me-Can cohort (prospective cohorts) Austria, Norway, and Sweden 1972–2006	587 700 Men and women Incidence	Oesophageal squamous cell carcinoma ICD-7: 150	BMI, quintiles Q1 Q2 Q3 Q4 Q5 [P _{trend}] per 5 kg/m ²		55 1.00 29 0.50 (0.32–0.79) 46 0.76 (0.51–1.12) 30 0.46 (0.30–0.72) 24 0.38 (0.23–0.62) [< 0.0001] 0.62 (0.50–0.79)	Sex, age, study cohort, smoking status	

BMI, body mass index (in kg/m²); CI, confidence interval; EPIC, European Prospective Investigation into Cancer and Nutrition; ICD, International Classification of Diseases; NIH-AARP, National Institutes of Health–AARP Diet and Health Study; NSAID, non-steroidal anti-inflammatory drug; SES, socioeconomic status; WC, waist circumference; yr, year or years

Table 2.2.2b Case-control studies of measures of body fatness and cancer of the oesophagus

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments	
Vaughan et al. (1995) USA (13 counties of Western Washington State) 1993–1990	EAC: Men and women: 133 Population	BMI, percentiles			Age, sex, education level, race, cigarette use, alcohol consumption	BMI percentiles based on sex- specific distribution in controls (1 yr before diagnosis in cases, 1 yr before interview in controls)	
		1–10%	12	1.6 (0.7–3.6)			
	ESCC: Men and women: 106 Population	10–49%	43	1.0			
		50–89%	50	1.2 (0.7–2.1)			
		90–100%	26	2.5 (1.2–5.0)			
		BMI, percentiles					
1–10%	34	3.2 (1.4–7.1)					
10–49%	41	1.0					
50–89%	24	0.7 (0.3–1.4)					
90–100%	6	0.2 (0.1–1.0)					
Chow et al. (1998) USA 1993–1995	EAC: Men and women: 292 Population	BMI up to 1 yr before diagnosis (sex-specific)			Geographical location, age, sex, race, cigarette smoking, respondent status	No effect modification was observed by history of gastro- oesophageal reflux disease	
		Men:	Women:	45			1.0
		< 23.12	< 21.95	63			1.3 (0.8–2.2)
		23.12–25.08	21.95–24.12	85			2.0 (1.3–3.3)
		25.09–27.31	24.13–27.43	99			2.9 (1.8–4.7)
	≥ 27.32	≥ 27.44		< 0.0001			
	[<i>P</i> _{trend}]						
	ESCC: Men and women: 220 Population	BMI up to 1 yr before diagnosis (sex-specific)					
		Men:	Women:	79			1.0
		< 23.12	< 21.95	50			0.5 (0.3–0.9)
23.12–25.08		21.95–24.12	53	0.8 (0.5–1.3)			
25.09–27.31		24.13–27.43	38	0.6 (0.3–1.0)			
≥ 27.32	≥ 27.44		< 0.11				
[<i>P</i> _{trend}]							
Lagergren et al. (1999) Sweden 1995–1997	EAC: Men and women: 189 Population	BMI 20 yr before interview			Age, sex, tobacco smoking, alcohol consumption, SES, reflux symptoms, intake of fruits and vegetables, energy intake, physical activity	No differences were observed in the associations for both cancer types when stratifying by presence of reflux symptoms	
		< 22	10	1.0			
		22–24.9	68	3.2 (1.6–6.7)			
		25–30	89	6.9 (3.3–14.4)			
		> 30	22	16.2 (6.3–41.4)			
[<i>P</i> _{trend}]		< 0.001					

Table 2.2.2b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments
Lagergren et al. (1999) (cont.)		BMI at age 20 yr, quartiles (sex-specific)				
		Men:				
		< 20.7	28	1.0		
		20.7–22.1	29	0.9 (0.5–1.6)		
		22.2–23.7	51	1.6 (0.9–2.8)		
		> 23.7	81	2.7 (1.6–4.6)		
		[<i>P</i> _{trend}]		< 0.001		
	ESCC:	BMI 20 yr before interview				
	Men and	< 22	48	1.0		
	women: 820	22–24.9	67	1.0 (0.6–1.7)		
	Population	25–30	42	1.3 (0.8–2.3)		
		> 30	10	2.0 (0.8–4.9)		
		[<i>P</i> _{trend}]		[0.12]		
		BMI at age 20 yr, quartiles (sex-specific)				
		Men:				
		< 20.7	36	1.0		
		20.7–22.1	38	1.2 (0.7–2.1)		
		22.2–23.7	40	1.4 (0.8–2.4)		
		> 23.7	53	1.8 (1.1–3.1)		
		[<i>P</i> _{trend}]		[0.03]		
Wu et al. (2001)	EAC:	BMI at age 40 yr, quartiles (sex-specific)				
USA	Men and	Men:	202 total			Smoking, sex, race,
1992–1997	women: 222	≤ 22		1.00		birthplace, education
	Population	> 22–25		1.13 (0.7–1.7)		level
	(proxy control)	> 25– ≤ 27		1.76 (1.1–2.9)		
		> 27		2.78 (1.7–4.4)		
		[<i>P</i> _{trend}]		< 0.0001		
		BMI at age 20 yr, quartiles (sex-specific)				
		Men:	207 total			
		≤ 20		1.00		
		> 20–22		1.23 (0.8–1.9)		
		> 22– ≤ 24		1.34 (0.9–2.1)		
		> 24		1.77 (1.1–2.7)		
		[<i>P</i> _{trend}]		[0.011]		

Table 2.2.2b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments
de Jonge et al. (2006) The Netherlands 2003–2005	EAC: Men and women: 91 Hospital	BMI 10 yr before questionnaire			Age, sex, education level, smoking status, alcohol consumption, reflux symptoms	Controls were patients with Barrett oesophagus
		< 25	29	1.0		
		> 25	58	1.8 (1.1–3.3)		
		BMI at age 20 yr				
		< 25	63	1.0		
		> 25	20	2.6 (1.2–5.5)		
Anderson et al. (2007) Ireland 2002–2004	EAC: 227 (192 men and 35 women) Population	Current BMI, tertiles			Sex, age at interview date, smoking status, alcohol consumption, years of full-time education, job type, gastro-oesophageal reflux	
		< 25.8	115	1.00		
		25.8–29.0	54	0.35 (0.21–0.58)		
		> 29.0	50	0.33 (0.20–0.56)		
		BMI 5 yr before, tertiles				
		< 25.0	51	1.00		
		25.0–28.1	55	1.74 (0.66–1.97)		
		> 28.1	120	2.69 (1.62–4.46)		
BMI at age 21 yr						
		< 22.1	55	1.00		
		22.1–24.1	64	1.10 (0.65–1.25)		
		> 24.1	96	1.81 (1.08–3.02)		
Löfdahl et al. (2008) Sweden 1995–1997	EAC + EJAC: Men: 388 Women: 63 Population	BMI 20 yr before interview			Age, education level, alcohol consumption, cigarette smoking, intake of fruits and vegetables, <i>Helicobacter pylori</i> infection Maximum and minimum adult BMI, also adjusted for gastro- oesophageal reflux	The associations for maximum adult BMI and for minimum adult BMI were weaker, but also showed a stronger association in women than in men
			Men:			
		< 22	45	1.0		
		22–24.9	143	1.5 (1.0–2.3)		
		25–29.9	164	2.7 (1.8–4.1)		
		≥ 30	36	5.4 (2.6–10.8)		
			Women:			
		< 22	12	1.0		
		22–24.9	25	2.4 (0.9–6.0)		
		25–29.9	16	4.3 (1.4–13.1)		
≥ 30	10	10.3 (2.6–42.3)				

Table 2.2.2b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments	
Whiteman et al. (2008) Australia 2001–2005	EAC: Men and women: 367 Population	BMI in the last year				Age, sex, state, household income, cumulative smoking history, mean alcohol consumption, frequency of aspirin use in the 5 yr before diagnosis	Results did not significantly change when additionally adjusted for gastro-oesophageal reflux; significantly higher risk in men than in women; no significant associations or trend between change in BMI and risk of EAC or EJAC
		< 18.5	1	0.3 (0.0–2.6)			
		18.5–24.9	71	1.0			
		25.0–29.9	150	1.4 (1.0–1.9)			
		30.0–34.9	89	2.7 (1.8–3.9)			
		35.0–39.9	25	3.1 (1.8–5.5)			
		≥ 40	16	7.0 (3.3–15.0)			
		[<i>P</i> _{trend}]		< 0.001]			
		Maximum BMI					
		< 18.5	1	0.9 (0.1–8.7)			
	18.5–24.9	39	1.0				
	25.0–29.9	136	1.4 (0.9–2.0)				
	30.0–34.9	114	2.5 (1.6–3.7)				
	35.0–39.9	43	4.1 (2.4–6.8)				
	≥ 40	24	5.2 (2.7–9.9)				
	[<i>P</i> _{trend}]		< 0.001]				
	BMI at age 20 yr						
	< 18.5	14	0.8 (0.4–1.4)				
	18.5–24.9	227	1.0				
25.0–29.9	81	1.7 (1.2–2.3)					
30.0–34.9	13	2.6 (1.3–5.2)					
35.0–39.9	5	3.6 (1.0–13.0)					
[<i>P</i> _{trend}]		< 0.001]					
EJAC: Men and women: 426 Population	BMI in the last year						
	< 18.5	1	0.2 (0.0–1.7)				
	18.5–24.9	107	1.0				
	25.0–29.9	168	1.1 (0.8–1.4)				
	30.0–34.9	98	1.9 (1.3–2.6)				
	35.0–39.9	27	2.0 (1.2–3.4)				
	≥ 40	9	2.6 (1.1–6.2)				
[<i>P</i> _{trend}]		< 0.001]					

Table 2.2.2b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments	
Whiteman et al. (2008) (cont.)		Maximum BMI					
		< 18.5	0	–			
		18.5–24.9	55	1.0			
		25.0–29.9	178	1.3 (0.9–1.8)			
		30.0–34.9	122	1.9 (1.3–2.7)			
		35.0–39.9	47	2.9 (1.8–4.6)			
		≥ 40	13	2.1 (1.1–4.2)			
		[<i>P</i> _{trend}]			[< 0.001]		
		BMI at age 20 yr					
		< 18.5	9	0.4 (0.2–0.8)			
		18.5–24.9	282	1.0			
		25.0–29.9	97	1.6 (1.2–2.1)			
30.0–34.9	13	2.1 (1.0–4.1)					
≥ 35.0	2	1.1 (0.2–5.9)					
[<i>P</i> _{trend}]				[< 0.001]			
Olsen et al. (2011) Australia 2002–2005	EAC: Men and women: 364 Population	BMI 1 yr before				Age, sex, education level, NSAID use, smoking status, heartburn/acid reflux in the past 10 yr	
		18–24.9	71	1.0			
		25–29.9	149	1.4 (1.0–2.0)			
		30–34.9	89	2.5 (1.7–3.6)			
		≥ 35	40	3.7 (2.2–6.2)			
	Overweight or obese		1.8 (1.3–2.5)				
	EJAC: Men and women: 425 Population	BMI 1 yr before					
		18–24.9	107	1.0			
		25–29.9	168	1.1 (0.8–1.5)			
		30–34.9	98	2.0 (1.4–2.9)			
≥ 35		36	2.5 (1.5–4.1)				
Overweight or obese		1.8 (1.3–2.5)					

Table 2.2.2b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments
Hoyo et al. (2012) International Barrett's and Esophageal Adenocarcinoma Consortium (BEACON) Pooled analysis of 10 case-control and 2 cohort studies from Australia, Europe, and USA	EAC: Men and women: 1997 Population EJAC: Men and women: 1900 Population	BMI < 25 25.0–29.9 30.0–34.9 35.0–39.9 ≥ 40 continuous BMI < 25 25.0–29.9 30.0–34.9 35.0–39.9 ≥ 40 continuous	577 862 331 86 41 1897 663 742 304 85 28 1822	1.00 1.54 (1.26–1.88) 2.39 (1.86–3.06) 2.79 (1.89–4.12) 4.76 (2.96–7.66) 1.09 (1.06–1.12) 1.00 1.28 (1.13–1.45) 2.08 (1.75–2.47) 2.36 (1.75–3.17) 3.07 (1.89–4.99) 1.07 (1.05–1.09)	Age, sex, smoking, education level, and other study-specific adjustment variables (e.g. study centre)	In stratified analyses, results were independent of the presence of symptoms of gastro-oesophageal reflux No differences in associations by sex
Lahmann et al. (2012) Australia 2002–2005	ESCC: Men and women: 287 Population	BMI in the last year, quintiles (sex-specific) Men: < 22.1 22.1– ≤ 24.6 24.6– ≤ 27.0 27.0– ≤ 31.9 > 31.9 [P _{trend}] Maximum BMI, quintiles (sex-specific) Men: ≤ 23.5 23.5– ≤ 26.0 26.0– ≤ 28.7 28.7– ≤ 33.9 > 33.9 [P _{trend}] BMI at age 20 yr < 25 ≥ 25 [P _{trend}] Women: < 23.7 23.7– < 25.6 25.6– ≤ 27.2 27.2– ≤ 29.7 > 29.7 Women: < 25.1 25.1– ≤ 27.0 27.0– ≤ 28.9 28.9– ≤ 31.7 > 31.7	108 65 35 41 38 90 73 42 43 39	1.00 0.61 (0.42–0.90) 0.32 (0.20–0.50) 0.40 (0.26–0.61) 0.36 (0.23–0.57) 1.00 0.78 (0.53–1.15) 0.49 (0.32–0.76) 0.45 (0.29–0.69) 0.44 (0.28–0.69) 1.00 0.85 (0.57–1.25) [< 0.001] [< 0.001] [< 0.40]	Age, sex, education level, alcohol consumption, smoking status, NSAID/aspirin use, physical activity BMI at age 20 yr (only for BMI in the last year)	

BMI, body mass index (in kg/m²); CI, confidence interval; EAC, oesophageal adenocarcinoma; EJAC, oesophagogastric junction adenocarcinoma; ESCC, oesophageal squamous cell carcinoma; GCAC, gastric cardia adenocarcinoma; NSAID, non-steroidal anti-inflammatory drug; SES, socioeconomic status; yr, year or years

Table 2.2.2c Mendelian randomization studies of measures of body fatness and cancer of the oesophagus

Reference Study	Characteristics of study population	Sample size	Exposure (unit)	Odds ratio (95% CI)	Adjustment for confounding	Comments
Thrift et al. (2014) Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS)	Subset of ethnically homogenous individuals from 14 studies in Australia, North America, and western Europe	5229 (999 EAC cases and 2169 controls)	1 kg/m ² increase based on a genetic risk score of 29 SNPs	1.23 (1.06–1.43)	NR	Similar associations in men and women. Associations with the genetic instrument were stronger than those of conventional epidemiological analyses in the same sample

CI, confidence interval; EAC, oesophageal adenocarcinoma; NR, not reported; SNP, single nucleotide polymorphism

References

- Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni JF Jr, Leitzmann M, Schatzkin A (2008). A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. *Eur J Cancer*, 44(3):465–71. doi:[10.1016/j.ejca.2007.12.009](https://doi.org/10.1016/j.ejca.2007.12.009) PMID:[18221867](https://pubmed.ncbi.nlm.nih.gov/18221867/)
- Anderson LA, Watson RG, Murphy SJ, Johnston BT, Comber H, Mc Guigan J, et al. (2007). Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. *World J Gastroenterol*, 13(10):1585–94. doi:[10.3748/wjg.v13.i10.1585](https://doi.org/10.3748/wjg.v13.i10.1585) PMID:[17461453](https://pubmed.ncbi.nlm.nih.gov/17461453/)
- Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. (1998). Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst*, 90(2):150–5. doi:[10.1093/jnci/90.2.150](https://doi.org/10.1093/jnci/90.2.150) PMID:[9450576](https://pubmed.ncbi.nlm.nih.gov/9450576/)
- Corley DA, Kubo A, Zhao W (2008). Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. *Cancer Epidemiol Biomarkers Prev*, 17(2):352–8. doi:[10.1158/1055-9965.EPI-07-0748](https://doi.org/10.1158/1055-9965.EPI-07-0748) PMID:[18268119](https://pubmed.ncbi.nlm.nih.gov/18268119/)
- de Jonge PJ, Steyerberg EW, Kuipers EJ, Honkoop P, Wolters LM, Kerkhof M, et al. (2006). Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. *Am J Gastroenterol*, 101(7):1421–9. doi:[10.1111/j.1572-0241.2006.00626.x](https://doi.org/10.1111/j.1572-0241.2006.00626.x) PMID:[16863542](https://pubmed.ncbi.nlm.nih.gov/16863542/)
- Engeland A, Tretli S, Bjørge T (2004). Height and body mass index in relation to esophageal cancer; 23-year follow-up of two million Norwegian men and women. *Cancer Causes Control*, 15(8):837–43. doi:[10.1023/B:-CACO.0000043434.21558.ea](https://doi.org/10.1023/B:-CACO.0000043434.21558.ea) PMID:[15456997](https://pubmed.ncbi.nlm.nih.gov/15456997/)
- Hoyo C, Cook MB, Kamangar F, Freedman ND, Whitman DC, Bernstein L, et al. (2012). Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. *Int J Epidemiol*, 41(6):1706–18. doi:[10.1093/ije/dys176](https://doi.org/10.1093/ije/dys176) PMID:[23148106](https://pubmed.ncbi.nlm.nih.gov/23148106/)
- IARC (2002). Weight control and physical activity. Lyon, France: IARC Press (IARC Handbooks of Cancer Prevention, Vol. 6). Available from: <http://publications.iarc.fr/376>.
- Lagergren J, Bergström R, Nyrén O (1999). Association between body mass and adenocarcinoma of the esophagus and gastric cardia. *Ann Intern Med*, 130(11):883–90. doi:[10.7326/0003-4819-130-11-199906010-00003](https://doi.org/10.7326/0003-4819-130-11-199906010-00003) PMID:[10375336](https://pubmed.ncbi.nlm.nih.gov/10375336/)
- Lahmann PH, Pandeya N, Webb PM, Green AC, Whitman DC; Australian Cancer Study (2012). Body mass index, long-term weight change, and esophageal squamous cell carcinoma: is the inverse association modified by smoking status? *Cancer*, 118(7):1901–9. doi:[10.1002/ncr.26455](https://doi.org/10.1002/ncr.26455) PMID:[21960146](https://pubmed.ncbi.nlm.nih.gov/21960146/)
- Lindblad M, Rodríguez LA, Lagergren J (2005). Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. *Cancer Causes Control*, 16(3):285–94. doi:[10.1007/s10552-004-3485-7](https://doi.org/10.1007/s10552-004-3485-7) PMID:[15947880](https://pubmed.ncbi.nlm.nih.gov/15947880/)
- Lindkvist B, Johansen D, Stocks T, Concin H, Bjørge T, Almquist M, et al. (2014). Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. *BMC Cancer*, 14(1):103. doi:[10.1186/1471-2407-14-103](https://doi.org/10.1186/1471-2407-14-103) PMID:[24548688](https://pubmed.ncbi.nlm.nih.gov/24548688/)
- Löfdahl HE, Lu Y, Lagergren J (2008). Sex-specific risk factor profile in esophageal adenocarcinoma. *Br J Cancer*, 99(9):1506–10. doi:[10.1038/sj.bjc.6604701](https://doi.org/10.1038/sj.bjc.6604701) PMID:[18841152](https://pubmed.ncbi.nlm.nih.gov/18841152/)
- Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA (2007). Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. *Gut*, 56(11):1503–11. doi:[10.1136/gut.2006.116665](https://doi.org/10.1136/gut.2006.116665) PMID:[17337464](https://pubmed.ncbi.nlm.nih.gov/17337464/)
- O'Doherty MG, Freedman ND, Hollenbeck AR, Schatzkin A, Abnet CC (2012). A prospective cohort study of obesity and risk of esophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. *Gut*, 61(9):1261–8. doi:[10.1136/gutjnl-2011-300551](https://doi.org/10.1136/gutjnl-2011-300551) PMID:[22174193](https://pubmed.ncbi.nlm.nih.gov/22174193/)
- Olsen CM, Pandeya N, Green AC, Webb PM, Whitman DC; Australian Cancer Study (2011). Population attributable fractions of adenocarcinoma of the esophagus and gastroesophageal junction. *Am J Epidemiol*, 174(5):582–90. doi:[10.1093/aje/kwr117](https://doi.org/10.1093/aje/kwr117) PMID:[21719746](https://pubmed.ncbi.nlm.nih.gov/21719746/)
- Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D; Million Women Study Collaboration (2007). Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *BMJ*, 335(7630):1134. doi:[10.1136/bmj.39367.495995.AE](https://doi.org/10.1136/bmj.39367.495995.AE) PMID:[17986716](https://pubmed.ncbi.nlm.nih.gov/17986716/)
- Renahan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008). Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet*, 371(9612):569–78. doi:[10.1016/S0140-6736\(08\)60269-X](https://doi.org/10.1016/S0140-6736(08)60269-X) PMID:[18280327](https://pubmed.ncbi.nlm.nih.gov/18280327/)
- Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr (2006). Relation of body mass index to cancer risk in 362,552 Swedish men. *Cancer Causes Control*, 17(7):901–9. doi:[10.1007/s10552-006-0023-9](https://doi.org/10.1007/s10552-006-0023-9) PMID:[16841257](https://pubmed.ncbi.nlm.nih.gov/16841257/)
- Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al.; MAGIC; Procardis Consortium (2010). Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet*, 42(11):937–48. doi:[10.1038/ng.686](https://doi.org/10.1038/ng.686) PMID:[20935630](https://pubmed.ncbi.nlm.nih.gov/20935630/)
- Steffen A, Huerta JM, Weiderpass E, Bueno-de-Mesquita HB, May AM, Siersema PD, et al. (2015). General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective

- Investigation into Cancer and Nutrition. *Int J Cancer*, 137(3):646–57. doi:[10.1002/ijc.29432](https://doi.org/10.1002/ijc.29432) PMID:[25598323](https://pubmed.ncbi.nlm.nih.gov/25598323/)
- Steffen A, Schulze MB, Pischon T, Dietrich T, Molina E, Chirlaque MD, et al. (2009). Anthropometry and esophageal cancer risk in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev*, 18(7):2079–89. PMID:[19567501](https://pubmed.ncbi.nlm.nih.gov/19567501/)
- Thrift AP, Shaheen NJ, Gammon MD, Bernstein L, Reid BJ, Onstad L, et al. (2014). Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study. *J Natl Cancer Inst*, 106(11):dju252. doi:[10.1093/jnci/dju252](https://doi.org/10.1093/jnci/dju252) PMID:[25269698](https://pubmed.ncbi.nlm.nih.gov/25269698/)
- Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. (2005). Prospective study of risk factors for esophageal and gastric cancers in the Linxian General Population Trial cohort in China. *Int J Cancer*, 113(3):456–63. doi:[10.1002/ijc.20616](https://doi.org/10.1002/ijc.20616) PMID:[15455378](https://pubmed.ncbi.nlm.nih.gov/15455378/)
- Vaughan TL, Davis S, Kristal A, Thomas DB (1995). Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev*, 4(2):85–92. PMID:[7742727](https://pubmed.ncbi.nlm.nih.gov/7742727/)
- Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, et al.; Australian Cancer Study (2008). Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. *Gut*, 57(2):173–80. doi:[10.1136/gut.2007.131375](https://doi.org/10.1136/gut.2007.131375) PMID:[17932103](https://pubmed.ncbi.nlm.nih.gov/17932103/)
- Wu AH, Wan P, Bernstein L (2001). A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). *Cancer Causes Control*, 12(8):721–32. doi:[10.1023/A:1011290704728](https://doi.org/10.1023/A:1011290704728) PMID:[11562112](https://pubmed.ncbi.nlm.nih.gov/11562112/)